Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Financial Times: Analysts say Pfizer moving too slow on M&A

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Mar 05, 2023 3:19pm

186 Views

Post# 35320138

RE:RE:RE:RE:Financial Times: Analysts say Pfizer moving too slow on M&A

As background to an unsolicited or unexpected bid is the noteable US$90 Billion acquisition of Warner-Lambert in 2000, not only for its scale but also for being one of the largest hostile takeovers of all time. Warner-Lambert had agreed to merge with American Home Products (AHP) in late 1999 when Pfizer decided to step in with an unsolicited offer for Warner-Lambert’s stock.

After a few months of terse exchanges between the management of both companies, Pfizer acquired Warner-Lambert three months later, leaving AHP with a considerable $1.8 Billion break-up fee.

<< Previous

Bullboard Posts

Next >>

Rig Count Soars as Utilization Surpasses Industry Averages